396 related articles for article (PubMed ID: 17539894)
1. Does co-administration of a non-selective opiate antagonist enhance acceleration of transit by a 5-HT4 agonist in constipation-predominant irritable bowel syndrome? A randomized controlled trial.
Foxx-Orenstein AE; Camilleri M; Szarka LA; McKinzie S; Burton D; Thomforde G; Baxter K; Zinsmeister AR
Neurogastroenterol Motil; 2007 Oct; 19(10):821-30. PubMed ID: 17539894
[TBL] [Abstract][Full Text] [Related]
2. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
3. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
[TBL] [Abstract][Full Text] [Related]
4. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
5. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation.
Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765
[TBL] [Abstract][Full Text] [Related]
7. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
8. Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.
Camilleri M; Vazquez-Roque M; Iturrino J; Boldingh A; Burton D; McKinzie S; Wong BS; Rao AS; Kenny E; Månsson M; Zinsmeister AR
Am J Physiol Gastrointest Liver Physiol; 2012 Jul; 303(1):G120-8. PubMed ID: 22517769
[TBL] [Abstract][Full Text] [Related]
9. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.
Camilleri M; McKinzie S; Fox J; Foxx-Orenstein A; Burton D; Thomforde G; Baxter K; Zinsmeister AR
Clin Gastroenterol Hepatol; 2004 Oct; 2(10):895-904. PubMed ID: 15476153
[TBL] [Abstract][Full Text] [Related]
10. Tegaserod: a serotonin 5-HT4 receptor agonist for treatment of constipation-predominant irritable bowel syndrome.
Cole P; Rabasseda X
Drugs Today (Barc); 2004 Dec; 40(12):1013-30. PubMed ID: 15645012
[TBL] [Abstract][Full Text] [Related]
11. DSP-6952, a novel 5-HT
Mine Y; Itakura T; Oku S; Asada R; Shimizu I
Eur J Pharmacol; 2018 May; 826():123-132. PubMed ID: 29428470
[TBL] [Abstract][Full Text] [Related]
12. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
Tegaserod Clinical Research Group
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
[TBL] [Abstract][Full Text] [Related]
13. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
Evans BW; Clark WK; Moore DJ; Whorwell PJ
Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.
Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P
Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice.
Lee MJ; Cho KH; Park HM; Sung HJ; Choi S; Im W
Eur J Pharmacol; 2014 Jul; 735():115-22. PubMed ID: 24769304
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
[TBL] [Abstract][Full Text] [Related]
18. Tegaserod: long-term treatment for irritable bowel syndrome patients with constipation in primary care.
Layer P; Keller J; Mueller-Lissner S; Rüegg P; Loeffler H
Digestion; 2005; 71(4):238-44. PubMed ID: 16024929
[TBL] [Abstract][Full Text] [Related]
19. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
Degen L; Matzinger D; Merz M; Appel-Dingemanse S; Osborne S; Lüchinger S; Bertold R; Maecke H; Beglinger C
Aliment Pharmacol Ther; 2001 Nov; 15(11):1745-51. PubMed ID: 11683688
[TBL] [Abstract][Full Text] [Related]
20. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome.
Baker DE
Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
